Drugs / Synthetic PreImplantation Factor
Synthetic PreImplantation Factor
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00517907 | Jan 2016 → Jan 2018 | graft versus host disease | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03593421 | Feb 2019 → Dec 2020 | — | Christopher O'Brien, MD | Withdrawn | No outcome recorded |
| Phase 2 | NCT03593460 | Jan → Nov 2019 | autoimmune hepatitis | Christopher O'Brien, MD | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synthetic PreImplantation Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03593460 ↗ |
| Known as | PIF-1 | “Preimplantation factor (PIF-1) is a novel, embryo-secreted peptide whose synthetic version matches the native peptide's properties.” NCT00517907 ↗ |
| Known as | Preimplantation factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00517907 ↗ |
| Known as | sPIF | “Synthetic PreImplantation Factor (sPIF)” NCT03593421 ↗ |
| Modality | Peptide | “novel peptide - preimplantation factor (PIF-1)” NCT00517907 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT00517907 ↗ |